Filing Flows › Teva Pharmaceutical Industries (TEVA) › R&D spending
Teva Pharmaceutical Industries (TEVA) R&D spending by quarter
Teva Pharmaceutical Industries' R&D spending was $297M in Q3 2026 (third quarter 2026), -69% from Q2 2026. Over the last 7 quarters it ranged from $222M (Q1 2026) to $970M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $297M | -69% | +16% |
| Q2 2026 | $970M | +337% | +298% |
| Q1 2026 | $222M | -17% | -10% |
| Q4 2025 | $267M | +4% | — |
| Q3 2025 | $256M | +5% | — |
| Q2 2025 | $244M | -1% | — |
| Q1 2025 | $247M | — | — |
Q3 2026 at a glance
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
Questions
What is Teva Pharmaceutical Industries' R&D spending?
Teva Pharmaceutical Industries' R&D spending was $297M in Q3 2026 (third quarter 2026), -69% from Q2 2026.
How has Teva Pharmaceutical Industries' R&D spending changed?
Over the last 7 quarters it ranged from $222M (Q1 2026) to $970M (Q2 2026).
Q3 2026 results → · How Teva Pharmaceutical Industries makes money →